21 & & & PART II & & & & & Item 5. Epigenetic control is therefore a critical factor in biology and medicine. The remaining "healthy" DNA fragments originate mainly from dead white blood cells. & &# The DNA attached to these nucleosomes is ctDNA. We believe the versatility of the Nu. We continue to research the use of our Nu. We are developing blood based Nu. The goal of this project is to investigate ways to specifically target ctDNA. Q® Capture reagents through distributor networks.& &# 183;Licensing of IP for laboratory developed patient testing services utilizing Nu. We are a clinical stage company and have incurred losses since our formation. & These activities require significant capital commitments and investment. We will rely on third parties to manufacture and supply our intended products. The global COVID-19 pandemic continues to rapidly evolve. Management continues to exercise tight cost controls to conserve cash. & The change was a result of the factors described above. For revenues and expenses, the weighted average exchange rate for the period is used. We conducted our audits in accordance with the standards of the PCAOB. The Company has one wholly owned subsidiary, Singapore Volition. & Useful lives are assigned to assets depending on their category. Q® Vet Cancer Screening Test and from the sale of nucleosomes. & The Company does not have future performance obligations under this revenue stream. Restricted stock units are valued based on the closing stock price on the date of grant. Leases & The Company adopted FASB issued Accounting Standards Update No. Funds are received in line with claims submitted for the agreed expenditure. On May 21, 2020, the underwriters exercised the overallotment option in full. Total remaining unrecognized compensation cost related to non-vested RSUs is $131,514. Comparative periods have not been restated. As of December 31, 2020, the principal balance payable was $255,725. & As of December 31, 2020, $nil is still to be paid by the Company under this agreement. & This agreement was amended in February 2020 to redefine a new clinical study. The agreement includes a six-month non-compete following termination of the agreement. Refer to Note 10(f) for the details. S-8 & 333-214118 & 10.7 & 10/14/16 & & 10.6# & Independent Director Agreement. & X 101.CAL & XBRL Taxonomy Extension Calculation Linkbase Document. & & & & & 200, to which the company is accountable. & & The recipients of the data are all located within the European Union. & database, training materials (presentations, syllabus, training notes, etc.) AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. & 5.The Corporation's Merger, Reorganization, Etc. & 7.Other Changes in the Corporation's Stock. & The Base Salary shall be referred to as the "Salary". a)Termination With Cause By Company. 16.SUCCESSORS AND ASSIGNS; ASSIGNMENT; INTENDED BENEFICIARIES. In the event of any conflict, the terms of this Agreement shall control. 183;working closely with the Group CEO to provide leadership and direction.& & &# The Exercise Price per share shall be US$4.90.& & The Company also generates product revenues from the sale& of its Nu.
